Cell Therapeutics Inc(NASDAQ:CTIC) has tied up with Novartis AG for reacquiring rights to two different cancer-fighting compounds such as pixantrone and paclitaxel poliglumex. The earlier agreement between...
Cell Therapeutics Inc(NASDAQ:CTIC) will reacquire the rights to Pixuvri and Opaxio from Novartis (NVS) on the condition that NVS receive “certain potential payments … based on...